VistaGen公布Fasedienol治疗社交焦虑症的Palisade-4三期公众演讲挑战试验顶线及事后分析数据

投资观察
Jul 06

VistaGen Therapeutics Inc.宣布了其候选药物Fasedienol用于社交焦虑症急性治疗的Palisade-4三期公众演讲挑战试验的顶线结果及事后分析数据。试验数据显示,Fasedienol在主要和次要终点上均未达到统计学意义上的显著改善。

然而,该药物的安全性和耐受性数据良好,与先前的临床试验结果保持一致。

公司计划与美国食品药品监督管理局(FDA)会面,就Fasedienol的未来三期试验及注册路径进行讨论。

值得注意的是,一项事后分析表明,在非常严重的社交焦虑症患者亚组中,Fasedienol显示出名义上的统计学显著性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10